Basking Biosciences develops targeted, reversible thrombolytic therapies for acute thrombotic conditions like ischemic stroke.
At a glance
- Founded: 2019
- HQ: Cary
- Sector: Biotech
- Stage: Series C
- Total raised: $55M
See the full company record.
Founders, funding history and recent signals. Free accounts open immediately.
Sourced company notes 3 topics
Notes on Basking Biosciences · last checked Oct 1, 2026
Overview
Clinical-stage biotechnology company developing BB-031, an RNA aptamer that inhibits von Willebrand Factor and is designed as the first reversible thrombolytic for acute ischemic stroke, currently in the Phase 2 RAISE trial. The filed address is a Cary mailbox, so the operating location is unconfirmed.
Funding
A Form D filed 2025-10-22 records $55,000,000 sold to 11 investors with a 2023-10-31 first sale. Company announcements describe a $55 million financing led by ARCH Venture Partners with Insight Partners, Platanus, Solas BioVentures, RTW, and Longview Ventures, structured with a $27.5 million tranche released in October 2025 on dosing the first patients in Part B of the Phase 2 trial.
Team
Julia C. Owens was appointed chief executive at the October 2025 tranche; ARCH co-founder Steve Gillis appears among the Form D related persons.
Listed roles
All Triangle rolesChecking listed roles…